Developer docs
API playgroundTry for free, no card

Search company profiles

Pheiron

Full company profile

uuid0000xjq

Namestring
Pheiron
Legal namestring
Pheiron Inc.
Websiteurl
pheiron.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Pheiron is an applied AI lab building proprietary models that underwrite biology risk in drug development. The company was founded in 2023 and operates with a small team of eight from dual headquarters in New York and Berlin, incorporated in Delaware as Pheiron Inc. It is backed by four specialist VCs: Ananda, Compound, Fusion Fund, and Hummingbird, with a single disclosed $4.2M funding round from Compound in June 2025.

The company's core product is the Pheiron Prediction Platform, which delivers two calibrated outputs for selected upcoming clinical trial readouts: a Biological Support score measuring the quality of underlying biology for a drug program, and a Probability of Trial Success estimate derived from Monte Carlo simulations across trial endpoints. Underlying these outputs are proprietary models trained on multimodal human population data spanning genetics, -omics, clinical records, and observational and interventional cohorts covering millions of lives. Pheiron runs primary analyses directly on this data to diligence novel mechanisms, rather than synthesizing existing literature. The company claims ~20x enrichment for successful programs over the base rate on historical target-indication phase transitions, compared to ~2x for human genetic support alone, and publishes predictions prospectively before readouts to enable industry benchmarking. Twenty predictions are publicly documented, with indications spanning Parkinson's disease, ulcerative colitis, and obesity.

Pheiron operates a B2B subscription model targeting biotech and pharmaceutical drug developers and biotech capital allocators, who use the platform to select winning programs, price biology risk, and identify mispriced opportunities. No pricing has been publicly disclosed, and no enterprise customers are named; the platform currently appears to function primarily through partnership arrangements. In addition to serving external partners, Pheiron states that it uses its own biological alpha to select and develop proprietary drug programs, extending from analytics into upstream drug development economics.

Short descriptiontext

Pheiron is an applied AI lab that builds proprietary models on multimodal human population data to underwrite biology risk and predict clinical trial success for biotech and pharma drug developers and biotech capital allocators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, clinical trial predictions, biology risk underwriting, pharmaceutical analytics, biotech investment analysis
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Software Publishers5132
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Access and Analysis Services
TypeSubscription Recurring
Description

B2B platform providing biological alpha analysis to biotech/pharma companies, capital allocators, and drug developers. Partners use the platform to identify mispriced biology opportunities, select winning programs, and inform investment decisions. The company selects and develops its own drug programs using the edge.

pheiron.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Pheiron operates an applied AI platform that builds proprietary models and runs primary analyses on large-scale multimodal human data (genetics, -omics, clinical records, observational and interventional cohorts) to underwrite biology risk in drug development. It publishes prospective predictions on upcoming clinical trial readouts, providing calibrated Biological Support scores and probability of trial success estimates that biotech, pharma, and capital allocators use to select high-probability drug programs. The company also uses its own edge to select and internally develop drug programs with the highest probability of success.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ~20x enrichment for successful programs over base rate on historical target-indication phase transitions
+1 more record
Product overview1 text field

Pheiron is an applied AI lab offering a prediction platform for biological alpha in drug development. The core product consists of their clinical trial prediction platform that delivers Biological Support scores and Probability of Success metrics for upcoming clinical readouts. Users access the platform through their website where they can view published predictions on trials across various therapeutic areas including Parkinson's disease, ulcerative colitis, obesity, and other indications.

Product and service1 record
1Pheiron Prediction Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion is a leading AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML models to identify novel therapeutics. Like Pheiron, it aims to systematically improve drug program selection through data-driven biology, though Recursion's primary differentiator is high-throughput lab automation rather than multimodal human data analysis.

TypeDirect peer
Description

Insitro uses ML on large-scale biological data (including patient-derived cells and genetics) to predict drug behavior and identify novel therapeutics. Its multimodal data approach and disease-modifying focus directly parallel Pheiron's biological alpha methodology, making it a strong direct competitor in the AI drug discovery space.

TypeDirect peer
Description

Schrödinger operates a physics-based computational platform for drug discovery and materials science, serving pharma companies with predictive modeling tools. It is comparable to Pheiron as a B2B platform that helps pharma companies make better program decisions, though its primary methodology is computational chemistry rather than multimodal human data.

TypeDirect peer
Description

Owkin applies AI to multimodal patient data from academic medical centers and hospitals to accelerate drug development and improve clinical trial design. Its federated learning approach to multimodal clinical data mirrors Pheiron's strategy of deriving novel biological evidence from primary multimodal human data analyses.

TypeDirect peer
Description

Atomwise uses AI for structure-based small molecule drug design, having built AtomNet to predict binding affinity and identify novel compounds. Like Pheiron, it serves biotech and pharma with predictive analytics that aim to reduce late-stage clinical failures through better early-stage decision-making.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and cloud computing to accelerate drug discovery and predict small molecule properties. It targets the same enterprise biotech/pharma customer base as Pheiron with predictive models that improve R&D efficiency, though focused on molecular design rather than clinical trial success probability.

7Tempus Labs
TypeBroad incumbent
Description

Tempus is a much larger precision medicine company that has built one of the world's largest libraries of multimodal clinical and molecular data, and uses AI to enable physicians and pharma to make data-driven decisions. It is comparable as a broad incumbent with overlapping multimodal data assets and pharma services, but operates at much larger scale with diversified offerings beyond clinical trial prediction.

TypeEmerging player
Description

Benchling provides cloud-based software for R&D in life sciences, including notebook, molecular biology, and process development tools. It serves a partially overlapping customer base (biotech R&D teams) with informatics infrastructure that complements Pheiron's predictive analytics, though Benchling focuses on lab data management rather than clinical outcome prediction.

TypeEmerging player
Description

Lantern Pharma uses its RADR AI platform to identify and develop oncology drug candidates, leveraging ML on multi-omic data to predict drug response. It is comparable as a smaller AI-driven oncology drug developer using data to underwrite biology risk, though more vertically integrated into drug development than Pheiron's primarily platform-focused approach.

TypeDirect peer
Description

Genesis Therapeutics uses AI and molecular simulation to predict drug-target interactions and develop novel therapeutics for undruggable targets. It serves a similar biotech/pharma enterprise customer base with predictive AI infrastructure and pursues a dual model of internal pipeline plus partnerships.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pheiron

AI Drug Discoverypheiron.com

Pheiron is an applied AI lab that builds proprietary models on multimodal human population data to underwrite biology risk and predict clinical trial success for biotech and pharma drug developers and biotech capital allocators.

What Pheiron does

Pheiron is an applied AI lab building proprietary models that underwrite biology risk in drug development. The company was founded in 2023 and operates with a small team of eight from dual headquarters in New York and Berlin, incorporated in Delaware as Pheiron Inc. It is backed by four specialist VCs: Ananda, Compound, Fusion Fund, and Hummingbird, with a single disclosed $4.2M funding round from Compound in June 2025.

The company's core product is the Pheiron Prediction Platform, which delivers two calibrated outputs for selected upcoming clinical trial readouts: a Biological Support score measuring the quality of underlying biology for a drug program, and a Probability of Trial Success estimate derived from Monte Carlo simulations across trial endpoints. Underlying these outputs are proprietary models trained on multimodal human population data spanning genetics, -omics, clinical records, and observational and interventional cohorts covering millions of lives. Pheiron runs primary analyses directly on this data to diligence novel mechanisms, rather than synthesizing existing literature. The company claims ~20x enrichment for successful programs over the base rate on historical target-indication phase transitions, compared to ~2x for human genetic support alone, and publishes predictions prospectively before readouts to enable industry benchmarking. Twenty predictions are publicly documented, with indications spanning Parkinson's disease, ulcerative colitis, and obesity.

Pheiron operates a B2B subscription model targeting biotech and pharmaceutical drug developers and biotech capital allocators, who use the platform to select winning programs, price biology risk, and identify mispriced opportunities. No pricing has been publicly disclosed, and no enterprise customers are named; the platform currently appears to function primarily through partnership arrangements. In addition to serving external partners, Pheiron states that it uses its own biological alpha to select and develop proprietary drug programs, extending from analytics into upstream drug development economics.

Pheiron firmographics

Firmographics
Name
Pheiron
Legal name
Pheiron Inc.
Website
https://pheiron.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Pheiron is an applied AI lab that builds proprietary models on multimodal human population data to underwrite biology risk and predict clinical trial success for biotech and pharma drug developers and biotech capital allocators.
Ownership category
akta.pro rank

Pheiron industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • AI drug discovery
  • Clinical trial predictions
  • Biology risk underwriting
  • Pharmaceutical analytics
  • Biotech investment analysis

Where Pheiron is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Pheiron business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Platform Access and Analysis Services: B2B platform providing biological alpha analysis to biotech/pharma companies, capital allocators, and drug developers. Partners use the platform to identify mispriced biology opportunities, select winning programs, and inform investment decisions. The company selects and develops its own drug programs using the edge.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Pheiron product offering

Product offering

Core offering

Pheiron operates an applied AI platform that builds proprietary models and runs primary analyses on large-scale multimodal human data (genetics, -omics, clinical records, observational and interventional cohorts) to underwrite biology risk in drug development. It publishes prospective predictions on upcoming clinical trial readouts, providing calibrated Biological Support scores and probability of trial success estimates that biotech, pharma, and capital allocators use to select high-probability drug programs. The company also uses its own edge to select and internally develop drug programs with the highest probability of success.

Product overview

Pheiron is an applied AI lab offering a prediction platform for biological alpha in drug development. The core product consists of their clinical trial prediction platform that delivers Biological Support scores and Probability of Success metrics for upcoming clinical readouts. Users access the platform through their website where they can view published predictions on trials across various therapeutic areas including Parkinson's disease, ulcerative colitis, obesity, and other indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pheiron Prediction Platform

Quantifiable outcome

  • ~20x enrichment for successful programs over base rate on historical target-indication phase transitions
  • +1 more outcomes

Companies that use Pheiron

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Pheiron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Pheiron partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Pheiron competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML models to identify novel therapeutics. Like Pheiron, it aims to systematically improve drug program selection through data-driven biology, though Recursion's primary differentiator is high-throughput lab automation rather than multimodal human data analysis.
  • Insitro: Insitro uses ML on large-scale biological data (including patient-derived cells and genetics) to predict drug behavior and identify novel therapeutics. Its multimodal data approach and disease-modifying focus directly parallel Pheiron's biological alpha methodology, making it a strong direct competitor in the AI drug discovery space.
  • Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science, serving pharma companies with predictive modeling tools. It is comparable to Pheiron as a B2B platform that helps pharma companies make better program decisions, though its primary methodology is computational chemistry rather than multimodal human data.
  • Owkin: Owkin applies AI to multimodal patient data from academic medical centers and hospitals to accelerate drug development and improve clinical trial design. Its federated learning approach to multimodal clinical data mirrors Pheiron's strategy of deriving novel biological evidence from primary multimodal human data analyses.
  • Atomwise: Atomwise uses AI for structure-based small molecule drug design, having built AtomNet to predict binding affinity and identify novel compounds. Like Pheiron, it serves biotech and pharma with predictive analytics that aim to reduce late-stage clinical failures through better early-stage decision-making.
  • XtalPi: XtalPi combines AI, quantum physics, and cloud computing to accelerate drug discovery and predict small molecule properties. It targets the same enterprise biotech/pharma customer base as Pheiron with predictive models that improve R&D efficiency, though focused on molecular design rather than clinical trial success probability.
  • Genesis Therapeutics: Genesis Therapeutics uses AI and molecular simulation to predict drug-target interactions and develop novel therapeutics for undruggable targets. It serves a similar biotech/pharma enterprise customer base with predictive AI infrastructure and pursues a dual model of internal pipeline plus partnerships.

Broad incumbents

  • Tempus Labs: Tempus is a much larger precision medicine company that has built one of the world's largest libraries of multimodal clinical and molecular data, and uses AI to enable physicians and pharma to make data-driven decisions. It is comparable as a broad incumbent with overlapping multimodal data assets and pharma services, but operates at much larger scale with diversified offerings beyond clinical trial prediction.

Emerging players

  • Benchling: Benchling provides cloud-based software for R&D in life sciences, including notebook, molecular biology, and process development tools. It serves a partially overlapping customer base (biotech R&D teams) with informatics infrastructure that complements Pheiron's predictive analytics, though Benchling focuses on lab data management rather than clinical outcome prediction.
  • Lantern Pharma: Lantern Pharma uses its RADR AI platform to identify and develop oncology drug candidates, leveraging ML on multi-omic data to predict drug response. It is comparable as a smaller AI-driven oncology drug developer using data to underwrite biology risk, though more vertically integrated into drug development than Pheiron's primarily platform-focused approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Pheiron social profiles

Digital presence

Pheiron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pheiron leadership team

Management profile

Number of profiles

Profiles8 records

Pheiron funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pheiron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pheiron

What does Pheiron do?

Pheiron operates an applied AI platform that builds proprietary models and runs primary analyses on large-scale multimodal human data (genetics, -omics, clinical records, observational and interventional cohorts) to underwrite biology risk in drug development. It publishes prospective predictions on upcoming clinical trial readouts, providing calibrated Biological Support scores and probability of trial success estimates that biotech, pharma, and capital allocators use to select high-probability drug programs. The company also uses its own edge to select and internally develop drug programs with the highest probability of success.

Is Pheiron a public or private company?

Pheiron is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pheiron founded?

Pheiron was founded in 2023. It employs 11 to 50 people.

Where is Pheiron based?

Pheiron is headquartered in Berlin, Germany, in the Europe region.

How does Pheiron make money?

One revenue line is on record: platform Access and Analysis Services.

Who are Pheiron's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Owkin, Atomwise, XtalPi and Genesis Therapeutics. Tempus Labs is listed as a broad incumbent. Emerging players are Benchling and Lantern Pharma.

Does Pheiron have an API?

No public API is recorded for Pheiron.

What industry is Pheiron in?

Pheiron's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals